MetLife Investment Management
AGIO icon

MetLife Investment Management’s Agios Pharmaceuticals AGIO Stock Holding History

MetLife Investment Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.28M Buy
34,470
+1,612
+5% +$48.9K 0.01% 1395
2026
Q1 		$1.11M Buy
32,858
+641
+2% +$18.2K 0.01% 1346
2025
Q4 		$877K Sell
32,217
-1,815
-5% -$63.7K ﹤0.01% 1505
2025
Q3 		$1.37M Hold
34,032
– – 0.01% 1282
2025
Q2 		$1.13M Hold
34,032
– – 0.01% 1244
2025
Q1 		$997K Sell
34,032
-547
-2% -$18.1K 0.01% 1366
2024
Q4 		$1.14M Buy
34,579
+1,916
+6% +$90K 0.01% 1345
2024
Q3 		$1.45M Hold
32,663
– – 0.01% 1183
2024
Q2 		$1.41M Buy
32,663
+3,600
+12% +$130K 0.01% 1156
2024
Q1 		$850K Hold
29,063
– – 0.01% 1391
2023
Q4 		$647K Hold
29,063
– – ﹤0.01% 1539
2023
Q3 		$719K Hold
29,063
– – 0.01% 1413
2023
Q2 		$823K Buy
29,063
+598
+2% +$14.9K 0.01% 1376
2023
Q1 		$654K Hold
28,465
– – ﹤0.01% 1476
2022
Q4 		$799K Hold
28,465
– – 0.01% 1327
2022
Q3 		$805K Sell
28,465
-1,922
-6% -$51.6K 0.01% 1304
2022
Q2 		$674K Sell
30,387
-1,660
-5% -$37.5K 0.01% 1456
2022
Q1 		$933K Buy
32,047
+11,726
+58% +$358K 0.01% 1379
2021
Q4 		$668K Hold
20,321
– – 0.01% 1333
2021
Q3 		$938K Sell
20,321
-1,793
-8% -$86.6K 0.01% 1144
2021
Q2 		$1.22M Buy
+22,114
New +$1.24M 0.01% 1068
2019
Q2 		– Sell
-207
Closed -$14.3K – 2426
2019
Q1 		$14.3K Buy
207
+138
+200% +$8.04K ﹤0.01% 2474
2018
Q4 		$3.18K Hold
69
– – ﹤0.01% 2511
2018
Q3 		$5.32K Buy
+69
New +$5.55K ﹤0.01% 2517

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Erste Asset Management
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Nomura Asset Management International
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

MetLife Investment Management's AGIO Position: Q2 2026 in Review

MetLife Investment Management increased its Agios Pharmaceuticals (AGIO) stake by 4.9% in Q2 2026, buying an estimated $48.9K and bringing the position to 34,470 shares worth $1.28M. The position accounts for 0.01% of the portfolio, ranked #1395.

MetLife Investment Management first reported a position in AGIO in Q3 2018 and has held it in 24 quarters since. The position peaked at $1.45M in Q3 2024. 238 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

  • MetLife Investment Management held 34,470 shares of Agios Pharmaceuticals worth $1.28M as of Q2 2026.
  • MetLife Investment Management bought 1,612 Agios Pharmaceuticals shares in Q2 2026, an estimated $48.9K.
  • Agios Pharmaceuticals made up 0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1395 holding.
  • MetLife Investment Management first reported a position in Agios Pharmaceuticals in Q3 2018 and has held it in 24 quarters since.
  • MetLife Investment Management's Agios Pharmaceuticals position peaked at $1.45M in Q3 2024.
  • 238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.